Surgery combined with adjuvant radiation and chemotherapy prolonged overall survival in stage IVC anaplastic thyroid cancer: a SEER-based analysis
- PMID: 38183567
- PMCID: PMC11246269
- DOI: 10.1007/s12020-023-03662-7
Surgery combined with adjuvant radiation and chemotherapy prolonged overall survival in stage IVC anaplastic thyroid cancer: a SEER-based analysis
Abstract
Background: Anaplastic thyroid carcinoma (ATC) is a rare but aggressive malignancy, which accounts for only 1-2% of all thyroid cancers. The median overall survival (OS) time for all stages patients is at about 5 months. The benefit of surgery combined with adjuvant radiation and chemotherapy in stage IVC anaplastic thyroid cancer is still controversial. The aim of this study is to investigating surgery combined with adjuvant radiation and chemotherapy and survival outcomes in stage IVC ATC patients.
Method: Anaplastic thyroid carcinoma patients from the Surveillance, Epidemiology, and End Results database from 2004 to 2016 were used to conduct a cross-sectional study in the analysis. The endpoint of this study was overall survival.
Results: The median OS of the overall population was 2.0 months. Multivariate analysis showed that age (<67 vs. ≥67 years old, P = 0.017, HR = 1.355, 95% CI: 1.057-1.738), tumor size (<7 cm vs. ≥7 cm, P = 0.001, HR = 1.579, 95% CI: 1.202-2.073), Surgery (thyroidectomy vs. non-surgery, P < 0.001, HR = 0.554, 95% CI: 0.401-0.766), radiation therapy (P < 0.001, HR = 0.571, 95% CI: 0.445-0.733) and chemotherapy (P = 0.003, HR = 0.684, 95% CI: 0.531-0.881) were independent prognostic factor for worse OS in stage IVC ATC patients. Surgery combined with adjuvant radiation and chemotherapy exhibited the better overall survival time for 4 months.
Conclusions: Surgery combined with adjuvant radiation and chemotherapy can improve overall survival in stage IVC ATC patients. We recommend surgical approach with fully evaluation combined with radiation therapy and chemotherapy for selected stage IVC ATC patients.
Keywords: Anaplastic thyroid carcinoma; Chemotherapy; Radiation therapy; Surgery.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures




Similar articles
-
Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer: A Single-Institution 21-Year Experience.JAMA Otolaryngol Head Neck Surg. 2023 Apr 1;149(4):300-309. doi: 10.1001/jamaoto.2022.5045. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 36757708 Free PMC article.
-
Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012.Thyroid. 2014 Nov;24(11):1600-6. doi: 10.1089/thy.2014.0004. Epub 2014 Sep 5. Thyroid. 2014. PMID: 25110922
-
Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.Thyroid. 2017 May;27(5):672-681. doi: 10.1089/thy.2016.0395. Epub 2017 Feb 16. Thyroid. 2017. PMID: 28068873 Free PMC article.
-
Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.J Cancer Res Clin Oncol. 2023 Jul;149(7):3527-3547. doi: 10.1007/s00432-022-04223-7. Epub 2022 Aug 12. J Cancer Res Clin Oncol. 2023. PMID: 35960373 Free PMC article.
-
Anaplastic thyroid cancer: prevalence, diagnosis and treatment.Minerva Endocrinol. 2008 Dec;33(4):341-57. Minerva Endocrinol. 2008. PMID: 18923370 Review.
Cited by
-
Machine learning-based prognostic model for patients with anaplastic thyroid carcinoma.Discov Oncol. 2025 Jan 21;16(1):70. doi: 10.1007/s12672-024-01703-9. Discov Oncol. 2025. PMID: 39836261 Free PMC article.
-
Diagnostic Evaluation of Anaplastic Thyroid Carcinoma in Core Biopsy Specimens: Morphologic, Immunohistochemical, Molecular, and Therapeutic Considerations.Endocr Pathol. 2025 Sep 4;36(1):32. doi: 10.1007/s12022-025-09876-x. Endocr Pathol. 2025. PMID: 40906053 Review.
-
Evaluation of conditional survival outcomes in patients with redefined anaplastic thyroid carcinoma.Front Endocrinol (Lausanne). 2025 Jun 10;16:1525869. doi: 10.3389/fendo.2025.1525869. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40556826 Free PMC article.
-
Trends in incidence, mortality, and conditional survival of anaplastic thyroid cancer over the last two decades in the USA.Front Endocrinol (Lausanne). 2025 Jun 4;16:1585679. doi: 10.3389/fendo.2025.1585679. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40535338 Free PMC article.
-
Development of a novel dynamic nomogram for predicting overall survival in anaplastic thyroid cancer patients with distant metastasis: a population-based study based on the SEER database.Front Endocrinol (Lausanne). 2024 Jul 4;15:1375176. doi: 10.3389/fendo.2024.1375176. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39027479 Free PMC article.
References
-
- Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001;91(12):2335–2342. doi: 10.1002/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1. - DOI - PubMed
-
- Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ, Jr., Di Cristofano A, Foote R, Giordano T, Kasperbauer J, Newbold K, Nikiforov YE, Randolph G, Rosenthal MS, Sawka AM, Shah M, Shaha A, Smallridge R, Wong-Clark CK. 2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021;31(3):337–386. doi: 10.1089/thy.2020.0944. - DOI - PMC - PubMed
-
- Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini A, Torregrossa L, Basolo F, Vitti P, Elisei R. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 2017;13(11):644–660. doi: 10.1038/nrendo.2017.76. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials